ResMed to sell software business MatrixCare for $490 million
MatrixCare generated about $220 million in revenue in FY26, and ResMed said sale proceeds will fund a share buyback and other corporate purposes.
- On Tuesday, ResMed announced a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners for $490 million in cash.
- ResMed aims to sharpen its focus on high-growth sleep, breathing, and connected care markets, making the divestiture strategically aligned with its long-term portfolio priorities.
- MatrixCare, which serves over 15,000 care providers, contributed approximately $220 million in revenue and $55 million in non-GAAP operating profit during the 2026 financial year.
- CEO Mick Farrell stated the sale reflects a "disciplined approach to portfolio management," with proceeds directed toward an accelerated share repurchase program and general corporate purposes.
- Pending regulatory approvals, the transaction is expected to close in the first quarter of ResMed's 2027 financial year as the company integrates its recent Noctrix acquisition.
15 Articles
15 Articles
ResMed sells its MatrixCare software business to Frazier for $490m
ResMed has agreed to sell MatrixCare, its home-health and senior-care software business, to the private equity firm Frazier Healthcare Partners for $490m in cash. The deal lets the medical-device maker part with a unit it had owned for years to focus on the machines that remain its core. MatrixCare is a decent-sized business in its […] This story continues at The Next Web
ResMed to sell software business MatrixCare for $490 million
July 7 (Reuters) - ResMed said on Tuesday it would sell its software business MatrixCare to private equity firm Frazier Healthcare Partners for $490 million in cash, as the health technology company sharpens its focus on sleep, breathing and home-bas...
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium









